We are leading the science in immunology through our research and development of advanced treatments for chronic, difficult to treat inflammatory diseases.
With two products on the market and a robust pipeline, our focus remains on bringing forward treatments for immunological diseases with significant unmet needs. In collaboration with Regeneron, we launched a first in class treatment for adults with moderate-to-severe atopic dermatitis; that same product is also approved in certain patients with moderate to severe asthma. Sanofi and Regeneron are currently conducting trials in atopic dermatitis in adolescents and the pediatric population as well as other diseases driven by allergic and other Type 2 inflammation including nasal polyps, eosinophilic esophagitis, and grass allergy. Our second product targets adults with moderate-to-severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints. A trial is also underway looking at the potential of this same product to treat juvenile idiopathic arthritis.
Above from left to right: Catherine, rheumatoid arthritis, USA; Hilde, atopic dermatitis, Norway; Vergard, atopic dermatitis, Norway